Skip to content

Deferred Taxes at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$211M-23.6%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$7.01B+189%
Amgen logo
AmgenAMGN
Biogen logo
BiogenBIIB
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
Gilead Sciences logo
Gilead SciencesGILD

Other financials

Income statement

See full
Revenue$1.1B+19.1%
Operating income$336.6M+702%
Net income$293.1M+417%
EPS (diluted)$4.43+391%

Balance sheet

See full
Cash & equivalents$667.5M-64.1%
Total debt$5.4B-0.1%
Total equity$4.5B+8.6%
Total assets$11.9B+2.8%

Cash flow

See full
Operating cash flow$408.2M-5.0%
CapEx$19.7M+41.7%
Free cash flow$388.5M-6.6%

Valuation

See full
Market cap$14.11B+54.4%
Enterprise value$18.85B+47.7%
P/S3.2×+0.9×

Profitability

See full
Operating margin-11.9%-28.1pp
Net margin-8.9%-20.5pp
FCF margin28.6%-8.6pp

Returns & leverage

See full
Return on equity-9.1%-21.2pp
Debt / equity1.2×-0.1×
Current ratio-1.3×

Where this comes from

Reported directly by Jazz Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:DeferredIncomeTaxLiabilitiesNet.

The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Jazz Pharmaceuticals's deferred taxes.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Jazz Pharmaceuticals's deferred taxes?
Jazz Pharmaceuticals (JAZZ) reported deferred taxes of $547.7M in Q1 2026.
How has Jazz Pharmaceuticals's deferred taxes changed year-over-year?
Jazz Pharmaceuticals's deferred taxes decreased by 18.4% year-over-year, from $670.8M to $547.7M.
What is the long-term trend for Jazz Pharmaceuticals's deferred taxes?
Over 5 years (2020 to 2025), Jazz Pharmaceuticals's deferred taxes has grown at a 35.4% compound annual growth rate (CAGR), from $130.4M to $594.5M.